Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Inify Laboratories AB AGM Information 2025

Apr 16, 2025

6123_rns_2025-04-16_26365e67-e703-4654-965b-3862444ede26.html

AGM Information

Open in viewer

Opens in your device viewer

Inify Laboratories - notice of Annual General Meeting on May 20, 2025

Inify Laboratories - notice of Annual General Meeting on May 20, 2025

Stockholm - April 16, 2025 - Inify Laboratories AB (publ), a unique laboratory

service provider within pathology and cancer diagnostics, hereby invites its

shareholders to Annual General Meeting on May 20, 2025. Please find attached the

invitation including agenda and details on how to register and vote.

The invitation is also available on the company's website: www.inify.com.

For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann

[email protected] or: [email protected].

About Inify Laboratories

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory

services within pathology. It uses a fully digital, standardized and AI-

supported workflow to optimize quality and response times, initially within

prostate.The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to

sample preparation, to reporting by a pathologist. The report is assisted by our

own AI, proven in clinical studies to have world-leading accuracy. The complete

workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off

fromContextVision (https://www.contextvision.com/), with 40 years of experience

within digital imaging for medical applications. It is listed onEuronext Growth

Oslo under the ticker

INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.